Published in Neuromolecular Med on January 01, 2005
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors | NCT03530800
Activity-dependent regulation of synapses by retrograde messengers. Neuron (2009) 1.73
Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci (2010) 1.48
Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des (2008) 1.26
Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem (2008) 1.15
Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res (2008) 1.08
The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol (2009) 1.05
Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl) (2011) 0.98
Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br J Pharmacol (2011) 0.97
Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience (2011) 0.96
Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS One (2013) 0.94
Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology (2007) 0.94
Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist (2014) 0.92
Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J Pharmacol Exp Ther (2009) 0.91
Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response (2007) 0.89
The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol (2011) 0.88
New horizons for newborn brain protection: enhancing endogenous neuroprotection. Arch Dis Child Fetal Neonatal Ed (2015) 0.87
Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol (2012) 0.85
Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. Neurochem Int (2010) 0.83
Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol (2015) 0.82
Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats. Neuropharmacology (2011) 0.80
Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage. PLoS One (2012) 0.79
Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res (2007) 0.79
The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation: implications for bone health. Stem Cells Int (2013) 0.78
Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro. Cell Mol Neurobiol (2010) 0.78
Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability. J Neurotrauma (2016) 0.77
Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci (2013) 0.77
Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast (2015) 0.77
Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. Neuropharmacology (2014) 0.76
The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats. Neurotoxicology (2014) 0.76
Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling. Exp Brain Res (2012) 0.76
Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models. Pediatr Neurol (2015) 0.76
Glucose concentration in culture medium affects mRNA expression of TRPV1 and CB1 receptors and changes capsaicin toxicity in PC12 cells. Iran J Basic Med Sci (2014) 0.75
Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. PLoS One (2013) 0.75
A flow cytometry assay to quantify intercellular exchange of membrane components. Chem Sci (2017) 0.75
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem (2004) 1.87
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Endocannabinoids and the control of energy balance. Trends Endocrinol Metab (2006) 1.74
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab (2013) 1.67
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2006) 1.54
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr (2009) 1.39
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci (2006) 1.37
An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab (2009) 1.36
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (2005) 1.33
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol (2008) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol (2003) 1.29
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol (2004) 1.24
Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem (2002) 1.22
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2008) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res (2005) 1.21
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des (2008) 1.21
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci (2007) 1.20
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie (2010) 1.19
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010) 1.19
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol (2009) 1.17
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 1.16
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J (2003) 1.15
Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med (2012) 1.15
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res (2007) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod (2002) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist (2010) 1.12
Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun (2005) 1.11
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des (2002) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis (2010) 1.09
Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med (2002) 1.09
Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol (2009) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A (2009) 1.08
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) (2007) 1.07
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res (2010) 1.07
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta (2008) 1.06
The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J (2002) 1.06
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology (2005) 1.06
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (2004) 1.05
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 1.05
Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis (2006) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J Neurosci (2008) 1.04
Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol (2010) 1.03
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacology (2012) 1.03
Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol (2004) 1.02
Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol (2006) 1.02
Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats. Obesity (Silver Spring) (2009) 1.02
Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor. J Med Chem (2012) 1.02
Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) (2011) 1.02
Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat (2005) 1.02
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J (2005) 1.02